Receive 30% off all Monoclonal IHC antibodies with code "MONO-IHC-30"! Offer valid for US customers and available internationally through distributors.

IL-31 Polyclonal Antibody

Applications

  • WB
  • ELISA
  • IHC-P
  • IHC-F
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Mouse

Predicted Reactivity

  • Rat
Overview
Catalog # bs-10070R
Product Name IL-31 Polyclonal Antibody
Applications WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Mouse
Predicted Reactivity Rat
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic peptide derived from mouse IL-31
Clonality Polyclonal
Clone # #REF!
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID 76399
Subcellular location Secreted
Synonyms Interleukin-31; 1700013B14RIK, IL31; interleukin-31 precursor.
Background Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
Application Dilution
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200